Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.75 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.71 |
| ▸ | ADH5 | P11766 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | RPA1 | P27694 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.60 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 6/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5017 | 0.98 | HPGDS (0.78) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL30810801 | 0.95 | HPGDS (0.75) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL2839742 | 0.86 | HPGDS (1.00) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL9984638 | 0.85 | ADH5 (0.95) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL25378122 | 0.84 | GP6 (1.00) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL30153550 | 0.81 | MEN1 (0.80) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL8783081 | 0.81 | MEN1 (0.80) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL16859786 | 0.81 | ADH5 (0.62) | HPGDSGP6ADH5ALDH1A1MEN1 | |
| SCHEMBL1250336 | 0.80 | ADH5 (0.61) | HPGDSGP6ADH5RPA1ATM | |
| SCHEMBL2932335 | 0.77 | ADH5 (0.71) | HPGDSGP6ADH5ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100540541-C | The method for preparing phenyltetrazole derivative | DIPHARMA SPA (IT) | 2009-09-16 | — | — | CN | disclosed |
| US-7385062-B2 | Process for the preparation of phenyltetrazole derivatives | DIPHARMA S.P.A. (IT) | 2008-06-10 | — | — | US | disclosed |
| EP-1660463-B1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | DIPHARMA FRANCIS SRL (IT) | 2007-12-05 | — | — | EP | disclosed |
| CN-1832931-A | A process for the preparation of phenyltetrazole derivatives | DIPHARMA SPA (IT) | 2006-09-13 | — | — | CN | disclosed |
| US-20060183916-A1 | Process for the preparation of phenyltetrazole derivatives | DIPHARMA S.P.A. (IT) | 2006-08-17 | — | — | US | disclosed |
| EP-1660463-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | Dipharma S.p.A. (IT) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014560-A1 | A PROCESS FOR THE PREPARATION OF PHENYLTETRAZOLE DERIVATIVES | DIPHARMA S.P.A. (IT) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183916-A1 | Process for the preparation of phenyltetrazole derivatives | AGTR2, ACE, AGTR1 | HPGDS 1118/4885GP6 1216/4885ADH5 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.